AAIC 2025 Abstract
Characterizing early symptomatic AD patients by visual and quantitative tau profiles
Trial in peoplePopulations
Abstract
Background: In the TRAILBLAZER‐ALZ 2 study (NCT04437511), tau pathology at screening was evaluated with flortaucipir Positron Emission Tomography (PET) with a combination of visual read (V) and quantitative (Q) standardized uptake value ratio (SUVr) approaches.
